Novel Treatment Approaches for Non-Small-Cell Lung Cancer: A 2016 Update
August 27, 2016, Houston, Texas
8:25 AM - 4:15 PM
Hyatt Regency Houston/Galleria 2626 Sage Road, Houston, Texas 77056 - Phone: (832) 803-1234
Program Director: John V. Heymach, MD, PhD
Jointly provided by

Educational Grants This activity is supported by educational grants from:
Lilly, USA, LLC, Boehringer Ingelheim Pharmaceuticals, Inc. and Novartis Pharmaceuticals Corporation

Statement of Need/Program Overview
This symposium is intended to improve care of patients with lung cancer by accelerating adoption of new guidelines and evidence-based practice change. The format will include didactic lectures from known opinion leaders, question and answer sessions, and ample opportunity for participant interaction with faculty.

Target Audience
This symposium is directed primarily to hematologists/oncologists, radiation oncologists, researchers, pharmacists, registered nurses, physician assistants, nurse practitioners and fellows in training interested in new development in lung cancer. No specific skill or knowledge other than a basic training in hematology/oncology is required for successful participation in this activity.

Physician Continuing Education Credit Designation
The A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care System designates this educational activity for a maximum of 6.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education Credit Designation
American Health Resources, Inc. is approved by the California Board of Registered Nursing, Provider # CEP 14254 and approved this program for 6.25 contact hours. Please check with licensing board to verify credits can be claimed in your state.

Pharmacist Continuing Education Credit Designation
This activity provides 6.25 contact hours (0.625 CEUs) - Knowledge based credits ACPE Universal Activity Number: 0280-9999-16-051-L01-P

Agenda Topics (Tentative)
- Molecular Profiling in the Treatment of NSCLC: Guidelines from the CAP, IASLC and AMP John V. Heymach, M, PhD
- Emerging Liquid Biopsy Mutation Testing for NSCLC - Lauren A. Byers, MD
- EGFR Inhibitors: Perspective on Molecular Markers and Patient Selection - Don L. Gibbons, MD, PhD
- ALK Inhibitors: Perspective on Molecular Markers and Patient Selection - TBD
- Emerging Strategies and Challenges Due to Secondary or Acquired EGFR and ALK TKI Resistance - TBD
- Identifying Therapeutic Options for NSCLC Patients without Action able Mutations - George R. Blumenschein, Jr, MD
- Should All Patients with Advanced NSCLC Receive Maintenance Therapy with Pemetrexed or Erlotinib? - TBD
- Immunotherapy with Anti-PD-1 (Nivolumab, Pembrolizumab) and Anti CTLA-4 (Ipilimumab) Antibodies in NSCLC - Don L. Gibbons, MD, PhD
- Immunotherapy with Anti-PD-L1 Antibodies (Atezolizumab and Durvalumab) in NSCLC - John V. Heymach, MD, PhD
- Immunotherapy and Targeted Therapy Options for Small Cell Lung Cancer - Lauren A. Byers, MD
- Supportive Care Issues in the Era of Targeted Therapy and Immunotherapy of NSCLC - David Hui, MD

For detailed information on faculty, learning objectives and agenda please refer to the www.cancernetus.com